To analyze the impact of different patterns of healthcare delivery on remission of rheumatoid arthritis (RA) patients treated with targeted therapies during the first wave (2020) and second/third waves (2021) of the pandemic compared to the pre-pandemic period (2019).
Methods
In this observational real-life study, data from RA patients treated with biologic or targeted synthetic drugs were extracted from a longitudinal registry. Clinical Disease Activity Index (CDAI) was analyzed in the same period from the 22nd of February to the 18th of May for three consecutive years. These three periods were characterized by different patterns of healthcare delivery: (1) before the pandemic (2019) only in-person visits, (2) during the first wave (2020) both in-person visits and telehealth, and (3) during the second/third waves (2021) only in-person visits. A generalized linear model with the binomial error was fitted to evaluate the difference in the proportion of patients in CDAI remission. Quantile regression was used to compare the median of CDAI in difficult-to-treat (D2T) patients.
Results
In the three periods, we included 407, 450, and 540 RA patients respectively. The percentages of patients in CDAI remission were similar in the three periods (prevalence ratio 1.07, p value 0.423 between 2020 and 2019, and 1.01, p-value 0.934 between 2021 and 2019). The CDAI remission rate was 40.55% (N = 163), 43.18% (N = 155) and 40.82% (N = 220) in 2019, 2020 and 2021, respectively. Among our cohort of D2T patients, CDAI remission was similar across the three periods (N = 30, 22.22%; N = 27, 23.68%; and N = 34, 21.52% respectively).
Conclusion
Although the pandemic has imposed changes in our healthcare delivery, these different strategies seem to be effective in ensuring satisfactory management of RA treated with targeted therapies. The approaches modulated in the context of the different periods have been a feasible compensation for ensuring disease control even in D2T patients.
HyrichKLMachadoPM. Rheumatic disease and COVID-19: Epidemiology and outcomes. Nat Rev Rheumatol2021; 17: 71–72.
2.
BonfaEGossecLIsenbergDA, et al.How COVID-19 is changing rheumatology clinical practice. Nat Rev Rheumatol2021; 17: 11–15.
3.
SmithACThomasESnoswellCL, et al.Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare2020; 26: 309–313.
4.
BatemanJCleatonN. Managing patients using telerheumatology: Lessons from a pandemic. Best Practice & Research Clinical Rheumatology2021; 35: 101662.
5.
MatsumotoRABartonJL. Telerheumatology: Before, during, and after a global pandemic. Curr Opin Rheumatol2021; 33: 262–269.
6.
GeorgeMDVenkatachalamSBanerjeeS, et al.Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic. J Rheumatol2021; 48: 603–607.
7.
D'SilvaKMWallaceZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol2021; 33: 255–261.
8.
IngegnoliFBuoliMPosioC, et al.COVID-19 related poor mental health and sleep disorders in rheumatic patients: A citizen science project. BMC Psychiatry2021; 21: 385.
9.
GaleaSMerchantRMLurieN. The mental health consequences of COVID-19 and physical distancing: The need for prevention and early intervention. JAMA Intern Med2020; 180: 817–818.
10.
CasagrandeMFavieriFTambelliR, et al.The enemy who sealed the world: Effects quarantine due to the COVID-19 on sleep quality, anxiety, and psychological distress in the Italian population. Sleep Med2020; 75: 12–20.
11.
MancusoCADuculanRJannat-KhahD, et al.Rheumatic disease-related symptoms during the height of the COVID-19 pandemic. HSS J2020; 16: 36–44.
12.
LandeweRBMachadoPMKroonF, et al.EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis2020; 79: 851–858.
13.
IngegnoliFCincinelliGLuppinoAF, et al.Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. Ann Rheum Dis2021; 80: 1243–1245.
14.
CiureaAPapagiannoulisEBurkiK, et al.Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: Results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis2021; 80: 238–241.
15.
ArnettFCEdworthySMBlochDA, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis RHeum1988; 31: 315–324.
16.
AletahaDNeogiTSilmanAJ, et al.2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis RHeum2010; 62: 2569–2581.
17.
NagyGRoodenrijsNMTWelsingPM, et al.EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis2021; 80: 31–35.
18.
NieuwenhuisWPde WitMPBoonenA, et al.Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the years 2010: Earlier identification but more severe patient reported outcomes. Ann Rheum Dis2016; 75: 2054–2056.
19.
MyasoedovaEDavisJMattesonEL, et al.Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014. Ann Rheum Dis2020; 79: 440–444.
20.
Guaracha-BasanezGAContreras-YanezIEstrada GonzalezVA, et al.Impact of a hybrid medical care model in the rheumatoid arthritis patient-reported outcomes: A non-inferiority crossover randomized study. J Telemed Telecare2022: 1357633X221122098.
21.
ThomasEEHaydonHMMehrotraA, et al.Building on the momentum: Sustaining telehealth beyond COVID-19. J Telemed Telecare2022; 28: 301–308.
22.
SnoswellCLChelbergGDe GuzmanKR, et al.The clinical effectiveness of telehealth: A systematic review of meta-analyses from 2010 to 2019. J Telemed Telecare2021: 1357633X211022907.
23.
SnoswellCLStringerHTaylorML, et al.An overview of the effect of telehealth on mortality: A systematic review of meta-analyses. J Telemed Telecare2021: 1357633X211023700.
24.
ZhangYWangJZhaoL, et al.Online management of rheumatoid arthritis during COVID-19 pandemic. Ann Rheum Dis2021; 80: e4.
25.
GlintborgBJensenDVTerslevL, et al.Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis. Rheumatology2021; 60: SI3–SI12.
26.
AbualfadlEIsmailFShereefRRE, et al.Impact of COVID-19 pandemic on rheumatoid arthritis from a multi-centre patient-reported questionnaire survey: Influence of gender, rural-urban gap and north-south gradient. Rheumatol Int2021; 41: 345–353.
27.
HassenLMAlmaghlouthIAHassenIM, et al.Impact of COVID-19 outbreak on rheumatic patients’ perceptions and behaviors: A cross-sectional study. Int J Rheum Dis2020; 23: 1541–1549.
28.
Fernandez-AvilaDGBarahona-CorreaJRomero-AlverniaD, et al.Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. Rheumatol Int2022; 42: 41–49.
29.
FavalliEGBiggioggeroMCrottiC, et al.Sex and management of rheumatoid arthritis. Clin Rev Allergy Immunol2019; 56: 333–345.
30.
MadsenSGDanneskiold-SamsøeBStockmarrA, et al.Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: A systematic review. Scand J Rheumatol2016; 45: 255–261.
31.
FarajiJMetzGAS. Aging, social distancing, and COVID-19 risk: Who is more vulnerable and why?Aging Dis2021; 12: 1624–1643.
32.
PoudelANZhuSCooperN, et al.Impact of COVID-19 on health-related quality of life of patients: A structured review. PLoS One2021; 16: e0259164.
33.
LebrasseurAFortin-BedardNLettreJ, et al.Impact of the COVID-19 pandemic on older adults: Rapid review. JMIR Aging2021; 4: e26474.
34.
Gallegos-RejasVMThomasEEKellyJT, et al.A multi-stakeholder approach is needed to reduce the digital divide and encourage equitable access to telehealth. J Telemed Telecare2023; 29: 73–78.
35.
To-MilesFHakanssonCWagmanP, et al.Exploring the associations among occupational balance and health of adults with and without inflammatory arthritis. Arthritis Care Res (Hoboken)2022; 74: 22–30.
36.
CraigLChurchillB. Dual-earner parent couples’ work and care during COVID-19. Gend Work Organ2021; 28: 66–79.
37.
AloushVGurfinkelAShacharN, et al.Physical and mental impact of COVID-19 outbreak on fibromyalgia patients. Clin Exp Rheumatol2021; 39: 108–114.
38.
IannuccelliCLucchinoBGioiaC, et al.Mental health and well-being during the COVID-19 pandemic: Stress vulnerability, resilience and mood disturbances in fibromyalgia and rheumatoid arthritis. Clin Exp Rheumatol2021; 39: 153–160.
39.
BaconAMWhiteLNormanA. Coping with fibromyalgia during the COVID-19 pandemic: Adjustment and wellbeing. Psychol Health2021: 1–16.
40.
SmyrniotiMELyrakosGMeindaniM, et al.The impact of the first wave of the COVID-19 pandemic on patients’ perceptions of chronic pain. J Pain Res2021; 14: 2571–2581.
41.
MesselinkMARoodenrijsNMTvan EsB, et al.Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: Results from a hackathon. Arthritis Res Ther2021; 23: 184.
42.
OchiSSonomotoKNakayamadaS, et al.Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST registry. Arthritis Res Ther2022; 24: 61.
43.
WatanabeRHashimotoMMurataK, et al.Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: The KURAMA cohort. Immunol Med2022; 45: 35–44.
44.
RoodenrijsNMTvan der GoesMCWelsingPMJ, et al.Difficult-to-treat rheumatoid arthritis: Contributing factors and burden of disease. Rheumatology2021; 60: 3778–3788.
45.
NewmanSPRevensonTA. Coping with rheumatoid arthritis. Baillieres Clin Rheumatol1993; 7: 259–280.
46.
FlureyCAHewlettSRodhamK, et al.Coping strategies, psychological impact, and support preferences of men with rheumatoid arthritis: A multicenter survey. Arthritis Care Res (Hoboken)2018; 70: 851–860.
47.
D'OnofrioBDe StefanoLPalermoBL, et al.Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19. Ann Rheum Dis2021; 80: 1242–1243.
